TICKERNERD
Menu
SERASERAHealthcare · Medical Devices

SERA Stock Forecast: Sera Prognostics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.03
−0.98% on the day

The 4 Wall Street analysts covering Sera Prognostics, Inc. hold a median 12-month price target of $5.5 — +170.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$80.1M
Ticker Nerd rank
41 / 100
Median analyst target
$5.50
Analysts covering
4
Revenue$30K+76.5% y/y
Operating income−$10.0M
Net income−$9.1M
Free cash flow−$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.5%
1M
+2.0%
YTD
−31.2%
1Y
−33.9%
From 52W high
−45.9%
From 52W low
+27.7%
$1.59
$3.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SERA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sera Prognostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
78
Accruals
75
Growth
72
Revisions
49
Momentum
44
Quality
37
Volatility
31
Issuance
23
Value
18

Size (78): Smaller than most of the companies we track.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26SERAHigh $6.00Median $5.50Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $5.00Median $5.50High $6.00

The green dot is the last close — the median target sits +170.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 June 2026Craig-HallumInitiatesBuy$6.00
10 Aug 2023CitigroupMaintainsNeutral—
10 Nov 2022CitigroupMaintainsNeutral—
14 Sept 2022BerenbergInitiatesBuy—
29 Aug 2022OppenheimerMaintainsOutperform—
27 Apr 2022BerenbergInitiatesBuy—
30 Mar 2022CitigroupDowngradeNeutral—
19 Nov 2021OppenheimerInitiatesOutperform—
9 Aug 2021CitigroupInitiatesBuy—
9 Aug 2021Cowen & Co.InitiatesOutperform—
9 Aug 2021William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SERA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SERA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Sera Prognostics, Inc. returned −33.9% against +17.5% for the S&P 500, dividends included.

SERA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26SERAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Sera Prognostics, Inc. (SERA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 87% of US stocks

Price / sales
1144.0×

Cheaper than 1% of US stocks

Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
−1.0×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
76.5%

Higher than 91% of US stocks

Earnings growth (YoY)
76.5%

Higher than 80% of US stocks

Gross margin
−66.7%

Higher than 2% of US stocks

Operating margin
−33346.7%

Higher than 1% of US stocks

Net margin
−102.5%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−45.0%

Higher than 23% of US stocks

Return on assets
−23.5%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sera Prognostics, Inc. (SERA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sera Prognostics, Inc. has a market value of $80.1M and an enterprise value of $37.4M.

  • Revenue in the twelve months to 30 June 2026: $70K. The latest quarter grew 76.5% year on year.

  • Net income over the same four quarters: −$33.2M, a −47475.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.67.

  • Free cash flow in the twelve months to 30 June 2026: −$28.2M.

  • Shares outstanding: 39.4M.

  • Trailing P/E: −3.0×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sera Prognostics, Inc. employs 71 people — $985.9 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

SERA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SERASera Prognostics, Inc.$80.1M
41
LUNGPulmonx Corp.$76.3M
82
CVRXCVRx, Inc.$75.8M
33
HYPRHyperfine, Inc.$83.8M
50
ECORelectroCore, Inc.$86.7M
59
LNSRLENSAR, Inc.$90.7M
62
MBOTMicrobot Medical, Inc.$97.4M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sera Prognostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SERA news & analysis

1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.

PRNewsWire · 25 Aug 2026positive

A leading OB-GYN, Dr. Thaïs Aliabadi, highlights that preterm birth risk can be identified between weeks 18 and 21 of pregnancy, pointing to Sera Prognostics' PreTRM blood test and PRIME trial results showing early, low-cost intervention can reduce the earliest preterm births by more than half.

Why it matters — The piece spotlights the PreTRM test and favorable PRIME trial data, raising awareness of Sera Prognostics' product among expectant mothers and clinicians.

SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

PRNewsWire · 19 Aug 2026positive

Sera Prognostics, Inc. announced on August 19, 2026 that Scott Gleason has been appointed Chief Financial Officer, effective August 31, 2026. Gleason brings over 25 years of experience in healthcare, diagnostics, and capital markets to the company.

Why it matters — A new CFO with extensive healthcare and capital markets experience could be significant for SERA watchers given the company's focus on pregnancy biomarker diagnostics and its standing as a publicly traded firm.

Sera Prognostics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

Sera Prognostics reported modest second-quarter revenue and discussed progress on payer engagement, Illinois Medicaid policy, clinical evidence, and European regulatory preparations for its PreTRM Test-guided care platform.

Why it matters — SERA watchers would care because the update offers insight into the company's operational milestones and market-access strategy for its core PreTRM test.

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Sera Prognostics, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The event covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — A SERA watcher would care because the earnings call transcript provides a record of the company's latest quarterly financial performance and management's discussion of its business.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 12 Aug 2026negative

Sera Prognostics reported a Q2 loss of $0.18 per share, wider than both the Zacks Consensus Estimate of a $0.14 loss and the $0.16 loss reported in the same quarter last year. Revenue also fell short of expectations.

Why it matters — The larger-than-expected loss and revenue miss could raise concerns about the company's near-term financial performance and trajectory versus analyst expectations.

FAQ

Frequently asked questions about SERA stock

What is the SERA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Sera Prognostics, Inc. have a median 12-month price target of $5.5, with estimates ranging from $5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SERA stock a buy right now?

Of the 4 analysts covering Sera Prognostics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sera Prognostics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SERA?

As at 12 Sept 2026, Sera Prognostics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

Will SERA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +170.9% from the last close, and Ticker Nerd's factor model ranks Sera Prognostics, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SERA stock forecast for 2030?

No analyst covering Sera Prognostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $6 over the next 12 months.

How has SERA stock performed over the past year?

Sera Prognostics, Inc. returned -33.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sera Prognostics, Inc. do?

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care.

What is the latest news on SERA?

The most recent item we track (PRNewsWire, 25 Aug 2026): "1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.". A leading OB-GYN, Dr. Thaïs Aliabadi, highlights that preterm birth risk can be identified between weeks 18 and 21 of pregnancy, pointing to Sera Prognostics' PreTRM blood test and PRIME trial results showing early, low-cost intervention can reduce the earliest preterm births by more than half.

Company

About Sera Prognostics, Inc.

Sera Prognostics, Inc. Class A Common Stock represents ownership in Sera Prognostics, a women’s health diagnostics company focused on improving maternal and neonatal care. The company develops and commercializes blood-based biomarker tests and predictive analytics designed to help physicians assess pregnancy-related risks, with its flagship PreTRM test used to estimate the risk of spontaneous preterm birth in singleton pregnancies. Sera Prognostics applies proteomics and bioinformatics to identify clinically useful markers from blood samples, supporting earlier risk awareness in prenatal care. Its product and service portfolio centers on pregnancy biomarker discovery, test validation, and diagnostic reporting for healthcare providers in the United States. Headquartered in Salt Lake City, Utah, and founded in 2008, Sera Prognostics operates as a specialized medical diagnostics business serving the broader women’s health and precision medicine markets.

CEO Ms. Zhenya Lindgardt M.B.A. · 71 employees · United States · https://www.sera.com